Our company (formerly known as Guangzhou Recomgen Biotech Co., Ltd.) officially changed its name to "CSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO., LTD." on April 2, 2022, due to development needs. We will continue to expand the new indications of our product rhTNK-tPA to benefit the public. Meanwhile, we will, with the mammalian cell continuous culture platform technology, research and develop new drug varieties to provide better products for patients.